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2ABSTRACT
Prediction of peptide binding to major histocompatibility complex (MHC) molecules is a basis
for anticipating T cell epitopes, as well as epitope discovery-driven vaccine development.  In the human,
MHC molecules are known as human leukocyte antigens (HLAs), and are extremely polymorphic.  HLA
polymorphism is the basis of differential peptide binding until now limiting the practical use of current
epitope-prediction tools for vaccine development.  Here, we describe a web server (PEPVAC) optimized
for the formulation of multi-epitope vaccines with broad population coverage.  This optimization is
accomplished through the prediction of peptides that are to bind to several HLA molecules with similar
peptide binding specificity (supertypes).  Specifically, we offer the possibility of identifying promiscuous
peptide binders to five distinct HLA class I supertypes (A2, A3, B7, A24, B15).  We estimated the
phenotypic population frequency of these supertypes to be 95%, regardless of ethnicity.  Targeting these
supertypes for promiscuous peptide binding predictions results in a limited number of potential epitopes
without compromising the population coverage required for practical vaccine design considerations.
PEPVAC can also identify conserved MHC ligands, as well as those with a C-terminus resulting from
proteasomal cleavage.  The combination of these features with the prediction of promiscuous HLA class I
ligands, further limits the number of potential epitopes.
Availability: The PEPVAC server is hosted by the Dana-Farber Cancer Institute at the site
http://immunax.dfci.harvard.edu/PEPVAC/
3INTRODUCTION
T cells are key component of the adaptive immune system, playing a pivotal role fighting both
infectious agents and cancer cells (1).  T cell-based immune responses are driven by antigenic peptides
(epitopes), presented in the context of major histocompatibility complex (MHC) molecules (2).
Therefore, prediction of peptides that can bind to MHC molecules has become the basis for the
anticipation of T cell epitopes (3).  MHC molecules fall into two major classes, namely MHC class I
(MHCI) and MHC class II (MHCII).  Antigens presented by MHCI and MHCII are recognized by two
distinct sets of T cells, CD8+ T and CD4+ T cells, respectively.  Identification of T cell epitopes is
important for both understanding disease pathogenesis and vaccine design.  Thus, the availability of
computational methods that can readily identify potential epitopes from primary protein sequences, have
fueled a new paradigm in vaccine develpoment that is driven by this epitope-discovery.
A major complication to this vaccine development approach is the extreme polymorphism of the
MHC molecules.  In the human, MHC molecules are known as human leukocytes antigens (HLAs), and
there are hundreds of allelic variants of the class I (HLA I) and the class II (HLA II) molecules.  These
HLA allelic variants bind distinct sets of peptides as MHC polymorphism is the basis for distinct peptide
binding specificity (4), and are expressed at vastly variable frequencies in different ethnic groups (5).
This complexity suggests that a large number of HLA molecules will have to be targeted for peptide-
binding predictions, requiring so many peptides to elicit a broadly protective multi-epitope vaccine as to
be impractical.  Interestingly, groups of several HLA molecules (supertypes) can bind largely overlapping
sets of peptides (6,7).  Identification of these HLA supertypes facilitates epitope-based vaccine
development for the following reasons: first, targeting of representative HLA aleles from distinct
supertypes allow the immune response to be stimulated in a variety of genetic backgrounds; second,
selection of promiscuous peptide-binders to those alleles included within a given supertype limits the
number of peptides to be considered without decreasing the spectrum of the immune response.
In this paper we describe a web server, PEPVAC, that allows the prediction of promiscuous
epitopes to 5 HLA I supertypes: A2 (A*0201-07, A*0209, A*6802), A3 (A*0301, A*1101, A*3101,
4A*3301, A*6801, A*6601), A24 (A*2402, B*3801), B7 (B*0702, B*3501, B*5101-02, B*5301,
B*5401), B15 (A*0101, B*1501_B62, B1502).  These supertypes were defined using a method based on
the clustering of the predicted peptide-binding repertoire of MHC molecules (8).  The combined
phenotypic frequency of these supertypes is greater than 95% for five major American ethnicities (Black,
Caucasian, Hispanic, Native American, and Asian). Thus, targeting these supertypes with epitope
predictions would potentially provide a population coverage ≥ 95%, regardless of ethnicity.
Peptides binding to HLA I molecules are potential CD8+ T cell epitopes.  In vivo, the C-terminus of these
antigenic epitopes result from the selective proteolysis of cytosolic proteins mediated by the proteasome
(9).  The proteasome is thus  important for determining these epitopes. Therefore, PEPVAC has also been
implemented with an algorithm for the identification of those peptides containing a C-terminus that is
likely to be the result of proteasomal cleavage.  Finally, PEPVAC also allows the prediction of conserved
epitopes from sequences with variability masked.  The combination of these two features serve to both,
refining the predictions of T cell epitopes and limiting the number of potential epitopes.
5PREDICTION OF PEPTIDE-MHCI BINDING.
The peptide binding mode of MHC I molecules differs from that of MHC II (10-12), and as result
the prediction of peptide-MHCII binding is less reliable than that of peptide-MHCI binding.  Thereby, we
have focused here in the prediction of MHCI ligands, a class that is specifically recognized by CD8+
cytotoxic T lymphocytes (CTLs).  Peptides binding to a specific MHCI molecule are related by sequence
similarity, and thus we use position specific scoring matrix (PSSMs) from aligned MHCI ligands as the
predictors of peptide-MHCI binding in combination with a dynamic algorithm.  PSSMs are also known as
profiles and weight-matrices and have previously been shown to be adequate tools for prediction of
peptide-MHC binding (13-16).  PSSMs are derived from block alignment of MHCI ligands which are of
the same length.  Such a restriction guarantees proper structural alignment of ligands, and subsequent
accuracy of the peptide binding predictions (13,14).  Given that MHCI-ligands are usually of 9 residues in
length, PSSMs used in this study are for the prediction of ligands of that same size (9 residues).  Accuracy
of prediction of peptide-MHCI binding using PSSMs varies depending on threshold and the targeted
MHCI molecule. On average, however, ROC analyses of the predictions at different thresholds result in
AUC values (Area Under Roc curve) above 0.8, indicating that these PSSMs are very for good predictors
of peptide-MHCI binding.  Furthermore, >80% of known CD8+ T cell epitopes can be predicted at a 2%
threshold from their protein sources
SUPERTYPES: IDENTIFICATION AND POPULATION COVERAGE ANALYSIS
We defined HLA I supertypes through clustering of predicted MHC peptide binding repertoires
(8). In  brief, the core of the method consists of the generation of a distance matrix whose coefficients are
inversely proportional to the peptide binders shared by any two HLA molecules (Figure 1).
Subsequently, this distance matrix is fed to a phylogenic clustering algorithm to establish the kinship
among the distinct HLA peptide binding repertoires.  Figure 2 shows a phylogenic tree built upon the
peptide binding repertoire of 55 HLA I molecules, using a Fitch and Margoliash clustering algorithm
(17).  We defined supertypes (Figure 2) as groups of HLA I alleles with ≥ 20% peptide binding overlap
6(pairwise between any pair of alleles).  The supertypes identified in this study include the A2, A3, B7,
B27 and B44 supertypes previously identified by Sidney-Sette et al.  Furthermore, we have also identified
two new supertypes, BX and B57 (Figure 2).  The cumulative phenotypic frequency (CPF) of these
supertypes is shown in Table I.  CPF was calculated using the gene and haplotype frequencies reported
for 5 distinct American ethic groups including Blacks, Caucasians, Hispanic, North America Natives and
Asians (18).  CPF represents the population coverage that would be provided by a vaccine composed of
epitopes restricted by the alleles included in the supertype.  The A2, A3 and B7 supertypes have the
largest CPF in the 5 studied ethnic groups, close to 90%, irrespective of ethnicity.  To increase the
population coverage to ≥ 95%, regardless of ethnicity, it is necessary to include at least two more
supertypes.  Specifically, the supertypes A2, A3, B7, B15 and A24/B44 represent the minimal supertypic
combinations with the indicated population coverage.  Alleles belonging to each of these supertypes are
shown in Figure 2 and Table I.
PEPVAC WEB SERVER
Following the HLA I supertypic analysis as discussed, we have implemented a tool for the
prediction of promiscuous peptide binders to a set of supertypes with a CPF greater than 95%,
irrespective of ethnicity.  We named this tool PEPVAC (Promiscuous Epitopes based VACcines), and it
is online at the site http://immunax.dfci.harvard.edu/PEPVAC/ hosted by the Molecular Immunology
Foundation/Dana-Farber Cancer Institute.  The web interface to PEPVAC is divided in several sections
that facilitate intuitive use (Fig. 3A).  Main features of the web server are discussed bellow.
Input and limitations
In PEPVAC, input query to carry epitope predictions is entered in the GENOME section (Fig 3A).  Input
consists of a single or various protein sequences in FASTA format. Only the standard 20 amino acid
residues are considered.  There are several translated genomes from pathogenic organisms that can be
selected as inputs.  More useful, a user-provided local file containing a set of protein sequences can be
uploaded to the server using the choose/browse bottom.  PEPVAC can also process files with protein
7sequences in which the variable sites have been masked with a dot "." symbol.  In that case, peptide-
binding predictions will be carried out only over consecutive stretches of 9 or more residues.  Sequences
with variable positions masked according to the Shannon Entropy variability metric (4,19) can be
obtained at the site http://immunax.dfci.harvard.edu/bioinformatics/Tools/sva.html.  Currently, there is
limit of 200 sequences and 50,000 symbols that can be processed per request. If such limits are exceed the
server will return an error.
Supertypes and thresholds
The A2, A3, B7, B15 and A24 (Figure 2 and Table I) supertypes have been chosen for promiscuous
peptide binding predictions in PEPVAC.  Only those peptides that are predicted to bind to all the alleles
included in the supertypes are returned in the output (Figure 3B). Threshold for the prediction of
promiscuous peptide binders in PEPVAC have been fixed to provide a reduced and manageable set of
promiscuous peptide binders to each supertype.  As an example, predicted promiscuous peptides to the
above 5 supertypes from a genome such as that of Influenza virus A (4160 amino acids distributed in 10
distinct open reading frames (ORF), represents only 5.51% (254 9mer peptides) of all possible peptides
(4617 9mer peptides).
Proteasome cleavage.
In PEPVAC, predictions of supertypic peptide binders are combined with prediction of
proteasomal cleavage using probabilistic language models derived from HLA I-restricted epitopes (14).
Currently, there are three optional models for proteasomal cleavage that differ in their
sensitivity/specificity ratio of the predictions as discussed elsewhere  (14). These models are selected
within the PROTEASOME CLEAVAGE section.  Model 1 has the highest sensitivity (~95%) and the
lower specificity (~60 %).  Conversely, Model 3 has the lowest sensitivity (65%) with the largest
specificity (80%).  Model two has a sensitivity and specificity around 70%.   Promiscuous peptide binders
containing a C-terminal end predicted to be the result of proteasomal cleavage are shown in violet in the
result page (Figure 3B).  In the previous example with the Influenza virus A, the list of promiscuous
peptide binders to the 5 selected supertypes decreases from 254 down to 170 peptides (3.7% of all 9mer
8peptides from Influenza virus A genome) after considering proteasomal cleavage using Model 1.
Furthermore, a combination of the predictions of peptide-MHCI binding and proteasomal cleavage
increases the specificity of the epitope predictions by discarding predicted peptide-MHCI binders that
experimentally are unable to elicit CD8+ T cell responses (20).
Output
The results page returned by PEPVAC is shown in Figure 3B.  This page first displays a summary of the
predictions, including the chosen selections, the number of predicted peptides and the minimum
population coverage provided by the supertypic selection, followed by the predicted peptide binders to
each of the selected supertypes (only A3 in the shown example).  Peptides are predicted to bind to all
alleles included in the supertype, and appear ranked with regard to the PSSMs of the first allele included
in the supertype. Relevant information about each sorted peptide includes its protein source as well as its
molecular weight.
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Figure 1. Strategy to define HLA I supertypes. HLA I supertypes are identified by clustering their peptide
binding repertoire (8).  The method consists of 4 basic steps.  (1) Predict the peptide binding repertoire (i,j
sets in figure) of each HLA I molecule from the same random protein using the relevant PSSMs in
combination with the RANKPEP scoring algorithm (13). (2)  Compute the number of common peptides
between the binding repertoire of any two HLA I molecules. (3)  Build a distance matrix whose
coefficients are inversely proportional to the peptide binding overlap between any pair of HLA I
molecules. (4)  Use a phylogenic clustering algorithm to compute and visualize HLA I supertypes
(clusters of HLA I molecules with overlapping peptide binding repertoires).
Figure 2.  HLA I peptide binding overlap and supertypes.  The figure shows an unroot dendrogram built
after clustering the overlap between the peptide binding repertoire of the indicated HLA I molecules.
Peptide binding repertoires of HLA I molecules were obtained from a random protein (1000 amino acids)
using the relevant PSSMs at a 2% peptide-binding threshold. This dendrogram reflects the relationship
between the peptide-binding specificities of HLA I molecules.  HLA I alleles with similar peptide binding
specificities branch together in groups or clusters.  The closer HLA I alleles branch, the larger is the
overlap between their peptide-binding repertoires. Supertypes (shadowed with different colors) consist of
groups HLA I alleles with at least a 20% peptide binding overlap (pairwise between any pair of alleles).
Figure. 3 The PEPVAC web server.  A) PEPVAC input page.  The page is divided into several sections.
E-MAIL, for obtaining the results via e-mail (optional). GENOMES,  where a selection of genomes from
pathogenic organisms are available, as well as the possibility of uploading a user-provided genome.
SUPERTYPES, the supertypes A2, A3, B7, A24, and B15 are available for selection. Alleles targeted for
peptide-biding predictions in each supertype are indicated.  The minimum population coverage of the
selected supertypes is calculated on the fly and shown on the relevant window. PROTEASOMAL
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CLEAVAGE, prediction of proteasomal cleavage using three optimal language models are carried out in
parallel to the peptide biding predictions. B) PEPVAC result page.  An example result page where the A3
supertype was selected for peptide-binding predictions from the genome of Influenza A virus is shown.
The result page first displays a summary of the predictions, followed by the predicted peptide binders to
each of the selected supertypes (only A3 in the shown example). Peptides highlighted in violet contain a
C-terminal residue that is predicted to be the result of proteasomal cleavage. If the proteasomal cleavage
filter is checked ON in the input page, only violet peptides will be shown.
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TABLES
Table 1. Cumulative phenotype frequency of defined supertypes
Supertype Alleles Blacks Caucasians Hispanics *N.A.Natives Asians
A2 A*0201-7, A*6802 43.7% 49.9% 51.8% 52.4% 44.7%
A3 A*0301, A*1101, A*3101, A*3301, A*6801, A*6601 35.4% 46.9% 41.5% 40.7% 47.9%
B7 B*0702, B*3501, B*5101-02, B*5301, B*5401 45.9% 42.2% 40.5% 52.0% 31.3%
B15 A*0101, B*1501_B62, B1502 13.06% 37.80% 16.75% 27.26% 21.04%
A24 A*2402, B*3801 15.5% 17.28% 25.85% 41.94% 35.0%
B44 B*4402, B*4403 10.4% 27.7% 17.15% 14.4% 10.1%
B57 B5701-02, B5801, B*1503 19.2% 10.3% 5.9% 5.8% 16.5%
ABX A*2902, B*4002 7.4% 11.3% 19.1% 16.3% 16.3%
B27 B*2701-06, B*2709, B*3909 2.3% 4.8% 5.1% 16.9% 4.7%
BX B*1509, B*1510, B*39011 3.1% 0.7% 4.2% 7.8% 4.1%
Cumulative phenotype frequency was obtained using the HLA I gene and haplotype frequencies published by Cao et al (18)
corresponding to the indicated 5 American ethnic groups.  Method for computing the cumulative phenotype frequency considered
the disequilibrium linkage between the HLA-A and -B gene and was based on that reported by Dawson et al (21) *North
American Natives.
15
FIGURES
Figure 1
16
Figure 2
17
Figure 3
